CYCN — Cyclerion Therapeutics Balance Sheet
0.000.00%
- $8.97m
- $3.27m
- 17
- 39
- 51
- 27
Annual balance sheet for Cyclerion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 94.9 | 54.4 | 54 | 13.4 | 7.57 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.47 | 0.127 | 0.1 | 0.096 | 0 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 101 | 58.5 | 55.5 | 14.8 | 8.02 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 79.8 | 50.3 | 1.47 | 1.22 | 0 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 186 | 115 | 59.3 | 18.1 | 13.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18.2 | 17 | 11.1 | 7.63 | 2.09 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 88.7 | 55.9 | 11.1 | 7.63 | 2.09 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 97.7 | 59.5 | 48.2 | 10.5 | 11.3 |
Total Liabilities & Shareholders' Equity | 186 | 115 | 59.3 | 18.1 | 13.4 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |